# Papilocare®: Effects on Regression of Histologically Confirmed Cervical Intraepithelial Lesions 1 and Tolerance

> **NCT04624568** · NA · COMPLETED · sponsor: **Centre Hospitalier Régional d'Orléans** · enrollment: 81 (actual)

## Conditions studied

- Squamous Intraepithelial Lesions of the Cervix
- Human Papilloma Virus Infection
- Cervix Lesion

## Interventions

- **DEVICE:** PAPILOCARE

## Key facts

- **NCT ID:** NCT04624568
- **Lead sponsor:** Centre Hospitalier Régional d'Orléans
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-11-17
- **Primary completion:** 2023-05-17
- **Final completion:** 2023-05-17
- **Target enrollment:** 81 (ACTUAL)
- **Last updated:** 2023-06-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04624568

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04624568, "Papilocare®: Effects on Regression of Histologically Confirmed Cervical Intraepithelial Lesions 1 and Tolerance". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT04624568. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*